Metabolex, a Hayward, Calif.-based drug company focused on diabetes and related metabolic diseases, has raised $10 million in Series C-1 funding, according to a regulatory filing. The company has now raised around $164 million in total VC since its 1998 inception. Shareholders include Alta Partners, Versant Ventures, Biotech Turnaround Fund (Netherlands), VantagePoint Venture Partners and Bay City Capital. (Source: PE Wire)


VentureBeat's mission is to be a digital town square for technical decision-makers to gain knowledge about transformative technology and transact. Our site delivers essential information on data technologies and strategies to guide you as you lead your organizations. We invite you to become a member of our community, to access:
  • up-to-date information on the subjects of interest to you
  • our newsletters
  • gated thought-leader content and discounted access to our prized events, such as Transform 2021: Learn More
  • networking features, and more
Become a member